FIELD: medicine, pharmaceutics.
SUBSTANCE: present invention refers to a compound of formula
wherein A represents 1,2,4-oxadiazol or 1,3,4-oxadiazol (of formula 
, 
or 
Ia), wherein star signs show a bond, which binds to a pyridine group of formula (I); R1 represents 3-pentyl, 3-methylbut-1-yl, cyclopentyl or cyclohexyl; R2 represents a methoxy group; R3 represents 2,3-dihidroxypropoxy group, -OCH2-CH(OH)-CH2-NHCO-CH2OH, -OCH2-CH(OH)-CH2N(CH3)-CO-CH2OH, -NHSO2CH3 or -NHSO2CH2CH3; and R4 represents ethyl or chlorine; or its pharmaceutically acceptable salts. The invention also refers to a pharmaceutical composition possessing S1P1/EDG1 receptor agonist activity, containing an effective amount of the compound of formula (I) or its pharmaceutically acceptable salt and pharmaceutically acceptable carrier.
EFFECT: pyridine-4-yl derivatives for preventing or treating diseases or disorders associated with the activated immune system.
26 cl, 4 tbl, 33 ex
| Title | Year | Author | Number |
|---|---|---|---|
| PYRIDIN-2-YL DERIVATIVES AS IMMUNOMODULATORY AGENTS | 2009 |
|
RU2494099C2 |
| 2-METHOXY-PYRIDIN-4-YL DERIVATIVES | 2012 |
|
RU2588141C2 |
| PYRIDIN-3-YL DERIVATIVES AS IMMUNOMODULATORY AGENTS | 2007 |
|
RU2454413C2 |
| PHENYL DERIVATIVES AND THEIR APPLICATION AS IMMUNOMODULATORS | 2007 |
|
RU2442780C2 |
| NEW THIOPHENE DERIVATIVES AS S1P1/EDG1 RECEPTOR AGONISTS | 2007 |
|
RU2442783C2 |
| USE OF 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | 2017 |
|
RU2759380C2 |
| C-3 AND C-17 MODIFIED TRITERPENOIDS AS HIV-1 INHIBITORS | 2017 |
|
RU2716502C2 |
| PYRIDIN-4-YL DERIVATIVES AS IMMUNOMODULATORY AGENTS | 2007 |
|
RU2447071C2 |
| 3-AMINOCYCLOPENTANCARBOXAMIDE DERIVATIVES | 2013 |
|
RU2641913C2 |
| SUBSTITUTED IMIDAZOPYRIDINES AS HDM2 INHIBITORS | 2013 |
|
RU2690663C2 |
